|Cross-section of multi-cellular bioprinted human liver tissue|
Last week represented a major inflection point in 3D bioprinting. Organovo, the San Diego based bioprinting company, introduced their first commercial product; a 3D printed human liver tissue that can help predict liver tissue toxicity in potential new drugs. Based on work done at the University of Missouri, this process will speed the development of new drugs by eliminating toxic compounds earlier in the discovery process.
This development, along with advancements in printing of orthopedic implants by companies like Arcam AB and improvements in 3D printed prosthetics, have made 2014 a watershed year for medical applications of 3D printing. Going forward, medical applications will be one of the largest and most important segments of the additive manufacturing market.
Are you thankful for any particular technologies?
You might also like:
Printing with Human Cells
Titanium Aluminide in the News
Drug Delivery Via 3D Print